Valuation: Aldeyra Therapeutics, Inc.

Market Cap 40.51M 36.9M 34.16M 30.9M 57.97M 3.78B 60.67M 413M 164M 2.04B 152M 149M 6.48B P/E 2026 *
-2.43x
P/E 2027 * -2.33x
Enterprise Value 40.51M 36.9M 34.16M 30.9M 57.97M 3.78B 60.67M 413M 164M 2.04B 152M 149M 6.48B EV / Sales 2026 *
-
EV / Sales 2027 * 7.12x
Free-Float
96.38%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Aldeyra Therapeutics, Inc.

1 day+6.62%
1 week+13.55%
Current month+27.70%
1 month+7.58%
3 months-54.72%
6 months-53.54%
Current year-86.19%
1 week 0.59
Extreme 0.59
0.73
1 month 0.53
Extreme 0.5271
0.75
Current year 0.53
Extreme 0.5271
5.93
1 year 0.53
Extreme 0.5271
5.93
3 years 0.53
Extreme 0.5271
7.2
5 years 0.53
Extreme 0.5271
11.97
10 years 0.53
Extreme 0.5271
16.7
Manager TitleAgeSince
Chief Executive Officer 54 2011-12-31
Director of Finance/CFO 61 2024-08-30
Chief Tech/Sci/R&D Officer - 2023-10-31
Director TitleAgeSince
Director/Board Member 54 2005-08-31
Director/Board Member 60 2009-04-30
Director/Board Member 76 2010-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Buy

Chief Executive Officer

250,000 0.4144%
3/27/26 Free

Chief Executive Officer

2,512,828 4.1767%
3/19/26 Buy

Chairman

70,000 0.1164%
Change 5-day change 1-year change 3-year change Capi.($)
+9.70%+13.55%-85.28%-73.10% 40.51M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.14%-1.96%+8.83%+89.74% 58.93B
+0.06%+0.51%+26.04%+87.89% 55.21B
-1.09%-4.06%+12.79%+112.40% 46.1B
-2.88%-7.14%+15.76%+22.63% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
-0.24%-9.14%+127.18%+637.37% 34.57B
+0.03%-1.80%+82.52%+57.74% 32.46B
+20.62%+22.42%-28.99%+487.08% 26.28B
Average +2.87%-1.61%+23.81%+153.73% 40B
Weighted average by Cap. +1.48%-2.69%+35.33%+148.99%

Financials

2026 *2027 *
Net sales - 5.69M 5.18M 4.8M 4.34M 8.14M 531M 8.52M 58M 23.01M 287M 21.35M 20.9M 910M
Net income -16.97M -15.46M -14.31M -12.94M -24.28M -1.58B -25.42M -173M -68.62M -856M -63.66M -62.32M -2.71B -16.53M -15.06M -13.94M -12.61M -23.65M -1.54B -24.76M -169M -66.84M -834M -62.01M -60.71M -2.64B
Net Debt - -
Projected Income Statement - Annual - Aldeyra Therapeutics, Inc.
Logo Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Employees
6
Date Price Change Volume
26-11-19 US$0.7209 +7.42% 749,553
26-11-18 US$0.6711 -3.29% 527,637
26-11-17 US$0.6939 +3.63% 743,908
26-11-16 US$0.6696 +4.01% 998,928
26-11-13 US$0.6438 +2.17% 764,019
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Aldeyra Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.6711USD
Average target price
6.600USD
Spread / Average Target
+883.46%
  1. Stock Market
  2. Stocks
  3. ALDX Stock